FDA slaps Pfizer for Zyvox professional ad

Share this article:
The Food and Drug Administration slapped Pfizer with a warning letter over a four-page journal ad for its Zyvox antibiotic.

The agency's Division of Drug Marketing, Advertising and Communications (DDMAC) said the ad failed to meet the fair balance requirement by omitting risk information, expanded the indication of the drug and made unsubstantiated claims of superiority to vancomycin for the treatment of pneumonia based on insufficient studies.

The letter, dated July 20, reads in part, "Your misleading promotion of Zyvox, and in particular, your unsubstantiated implied claims regarding its superiority to vancomycin, poses serious public health and safety concerns because of its potential to result in the inappropriate use of Zyvox, which is associated with increased toxicity relative to vancomycin."

Zyvox professional advertising is handled by Cline, Davis & Mann. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.